The global Legionella testing market is gaining importance as healthcare organizations, commercial facilities, hospitality businesses, and industrial operators place greater emphasis on water safety and the prevention of Legionnaires’ disease. Legionella bacteria can cause Legionellosis, including Legionnaires’ disease, a serious form of pneumonia that can require hospitalization and intensive care. Increasing awareness of waterborne infections, regulatory requirements, and the need for early detection are encouraging organizations to adopt routine monitoring and advanced testing technologies.

According to Grand View Research, the global Legionella testing industry is expanding as governments and public health authorities strengthen water management programs. Growing outbreaks and increased attention toward preventive testing are encouraging demand for solutions capable of detecting Legionella bacteria accurately and rapidly.

Market Valuation and Growth Outlook

Grand View Research provides the following key figures for the global Legionella testing industry:

• Market size in 2025: USD 369.9 million

• Estimated market size in 2026: USD 399.3 million

• Projected market size by 2033: USD 700.3 million

• CAGR, 2026–2033: 8.4%

• North America revenue share in 2025: 37.1%

• Water testing revenue share in 2025: 76.2%

• PCR revenue share in 2025: 37.4%

• Asia Pacific CAGR during the forecast period: 9.5%

The growth trajectory reflects increasing investment in environmental surveillance, water quality management, and diagnostic infrastructure. Facilities with complex water systems are becoming more focused on identifying contamination risks before they develop into major outbreaks. This is creating opportunities for traditional laboratory testing as well as faster molecular diagnostic technologies.

Download a free sample copy of the Legionella Testing Market report to understand detailed coverage and inclusions in the final report

Water Testing Remains the Leading Type

Water testing represented the largest type segment in 2025. The segment accounted for 76.2% of revenue, supported by regulations and water safety requirements implemented across several countries. Legionella can grow in complex building water systems, cooling towers, healthcare facilities, hotels, and other environments where water management is critical. Regular testing enables facility operators to identify potential contamination and take appropriate preventive measures.

Traditional culture-based testing continues to have an important role because of its established use and ability to identify Legionella. However, conventional approaches can require considerable time before results are available. This creates challenges when organizations need to respond quickly to potential contamination.

The industry is therefore moving toward advanced testing technologies that can reduce turnaround times. Automation and digitization are helping laboratories streamline testing workflows, reduce manual intervention, and improve consistency. Grand View Research notes that automation can facilitate up to 50% timesaving in diagnostic procedures.

PCR Technology Drives Advanced Detection

PCR emerged as the leading end-use technology in the Legionella testing industry, accounting for 37.4% of revenue in 2025. PCR-based testing is gaining attention because of its rapid detection capabilities, sensitivity, and ability to identify both viable and non-viable bacteria. These characteristics make molecular diagnostics particularly valuable when timely information is needed to support water safety decisions.

The growing adoption of molecular diagnostics is also encouraging companies to expand their product portfolios. Portable and field-based testing platforms can potentially reduce delays associated with transporting samples to centralized laboratories. This supports faster assessment of contamination and enables facility managers to take corrective measures more efficiently.

The IVD testing segment is also expected to experience significant growth. Urinary antigen tests and PCR are increasingly used alongside traditional culture methods, providing additional tools for identifying Legionella and supporting faster diagnosis.

Regulatory Focus Supports Market Expansion

Increasing regulatory attention to water safety is one of the major factors supporting demand. Governments and public health organizations are strengthening guidelines and monitoring practices for healthcare facilities, hospitality establishments, commercial buildings, and industrial infrastructure.

Preventive water management programs are encouraging organizations to conduct routine sampling and testing rather than waiting until an outbreak occurs. This shift toward proactive surveillance is creating sustained demand for Legionella detection solutions.

Recent outbreaks have further highlighted the importance of timely testing. Grand View Research notes that multiple European countries have experienced Legionnaires’ disease outbreaks, increasing awareness of early intervention and preventive water management.

Challenges Affecting Adoption

Despite strong growth prospects, the industry faces several challenges. Comprehensive Legionella monitoring programs can involve expenses related to routine sampling, laboratory testing, water system assessments, staff training, documentation, and corrective actions. These costs may limit adoption among smaller facilities and organizations operating under tight budgets.

Advanced molecular methods can also have higher implementation and operating costs compared with conventional culture-based approaches. In developing markets, limited awareness of Legionella-related risks and differences in regulatory enforcement can further restrict the adoption of routine testing programs.

Another challenge involves the limited number of manufacturers offering specialized Legionella testing technologies. However, continued innovation and investment could gradually improve accessibility and expand the range of available solutions.

Looking for more specific insights? Customize this report to suite your business needs

Regional Market Landscape

North America held the leading regional position in 2025, accounting for 37.1% of global revenue. The region benefits from increasing awareness of Legionnaires’ disease, stringent water safety requirements, established healthcare infrastructure, and investment in innovative diagnostic technologies. The U.S. represented the largest country-level market in the region.

Asia Pacific is expected to demonstrate the fastest growth, with a 9.5% CAGR during the forecast period. Rising healthcare investment, expanding healthcare infrastructure, increasing awareness of waterborne diseases, and improvements in diagnostic availability are supporting regional opportunities. China is also benefiting from rapid urbanization and industrialization alongside greater attention to preventive measures.

Competitive Landscape and Innovation

The competitive environment includes major diagnostics and biotechnology companies such as:

• Abbott

• Beckman Coulter, Inc. (Danaher Corporation)

• BD

• Bio-Rad Laboratories, Inc.

• BIOMÉRIEUX

• Eiken Chemical Co., Ltd.

• Hologic, Inc

• Pro Lab Diagnostics Inc.

• QIAGEN

• F. Hoffmann-La Roche Ltd.

• Takara Bio Inc.

• Thermo Fisher Scientific Inc.

For example, in September 2024, LuminUltra acquired Genomadix's Legionella testing assets, including commercialization rights for the Genomadix Cube qPCR platform. The platform is designed to support rapid field-based Legionella detection and reflects the industry's movement toward faster molecular testing.